NYSE:LLY

Eli Lilly and Stock Forecast, Price & News

$206.92

+6.38 (+3.18 %)

(As of 03/5/2021 12:00 AM ET)

Add

Compare

Today's Range

$200.88

Now: $206.92▼

$207.67

50-Day Range

$186.69

MA: $202.81▼

$212.72

52-Week Range

$117.06

Now: $206.92▼

$218.00

Volume3.88 million shs

Average Volume4.54 million shs

Market Capitalization$198.32 billion

P/E Ratio33.81

Dividend Yield1.64%

Beta0.37

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; Dicerna Pharmaceuticals, Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; Duke Clinical Research Institute for the prevention of chronic heart failure and mortality after an acute myocardial infarction; AbCellera Biologics Inc.; and Sermonix Pharmaceuticals Inc., as well as an agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Headlines

Lilly exec resigns after relationship that violated policy
February 9, 2021 | marketbeat.com

EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union
March 5, 2021 | finance.yahoo.com

UPDATE 1-EU regulator advises on use of Lilly's COVID-19 antibody cocktail
March 5, 2021 | finance.yahoo.com

EU regulator advises on use of Lilly's COVID-19 antibody cocktail
March 5, 2021 | finance.yahoo.com

EMA's Medicinal Committee Backs Eli Lilly's COVID-19 Antibody Therapy
March 5, 2021 | feeds.benzinga.com

Zoladex Market Report 2021 Growth Factors, Research Methodology With Impact of COIVD-19 and Global Forecast 2025
March 5, 2021 | marketwatch.com

Eli Lilly Will Unveil Alzheimer’s Drug Data Next Week. What to Watch.
March 5, 2021 | finance.yahoo.com

Eli Lilly (LLY) Stock Moves -0.72%: What You Should Know
March 4, 2021 | finance.yahoo.com

Eli Lilly's Tirzepatide Tops Novo's Semaglutide In Late-Stage Diabetes Study
March 4, 2021 | feeds.benzinga.com

Vir Stock Craters On Weak Data For GSK-Partnered Covid Treatment
March 3, 2021 | finance.yahoo.com

Why Is Lilly (LLY) Down 2.5% Since Last Earnings Report?
February 28, 2021 | finance.yahoo.com

Biden administration buys 100,000 doses of Lilly antibody drug
February 26, 2021 | msn.com

US government purchases 100K doses of Eli Lilly combination therapy to treat COVID-19
February 26, 2021 | msn.com

US Government Calls For Additional Eli Lilly COVID-19 Antibody Therapy
February 26, 2021 | benzinga.com

Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19
February 26, 2021 | finance.yahoo.com

Coronavirus Mutations: Why The Battle Against Covid Is Just Beginning
February 26, 2021 | finance.yahoo.com

Eli Lilly says U.S. government has agreed to buy at least 100,000 doses of its COVID antibody therapy
February 26, 2021 | finance.yahoo.com

UPDATE 1-U.S. to buy at least 100,000 doses of Lilly's COVID-19 antibody therapy
February 26, 2021 | finance.yahoo.com

Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions
February 25, 2021 | finance.yahoo.com

Lilly to Participate in Cowen Health Care Conference
February 24, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNYSE:LLY

Previous Symbol

CUSIP53245710

CIK59478

Webwww.lilly.com

Phone317-276-2000

Employees35,065

Year Founded1876

Debt

Debt-to-Equity Ratio3.27

Current Ratio1.36

Quick Ratio1.06

Price-To-Earnings

Trailing P/E Ratio33.81

Forward P/E Ratio27.37

P/E Growth1.57

Sales & Book Value

Annual Sales$22.32 billion

Price / Sales8.89

Cash Flow$7.90 per share

Price / Cash Flow26.19

Book Value$2.81 per share

Price / Book73.64

Profitability

EPS (Most Recent Fiscal Year)$6.04

Net Income$8.32 billion

Net Margins24.01%

Return on Equity166.45%

Return on Assets15.18%

Miscellaneous

Outstanding Shares958,426,000

Market Cap$198.32 billion

Next Earnings Date4/27/2021 (Confirmed)

OptionableOptionable

MarketRank^™

Overall MarketRank^™

2.12 out of 5 stars

Medical Sector

38th out of 1,968 stocks

Pharmaceutical Preparations Industry

14th out of 771 stocks

2.4 Analyst's Opinion

Consensus Rating
Eli Lilly and has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 10 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $192.60, Eli Lilly and has a forecasted downside of 6.9% from its current price of $206.92.
Amount of Analyst Coverage
Eli Lilly and has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.8 Community Rank

Outperform Votes
Eli Lilly and has received 1,030 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Eli Lilly and has received 842 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Eli Lilly and has received 55.02% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and and other stocks. Vote “Outperform” if you believe LLY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Yield
Eli Lilly and pays a meaningful dividend of 1.68%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Eli Lilly and has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Eli Lilly and is 56.29%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 42.61% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eli Lilly and insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $79,861,500.00 in company stock.
Percentage Held by Insiders
Only 0.09% of the stock of Eli Lilly and is held by insiders.
Percentage Held by Institutions
75.59% of the stock of Eli Lilly and is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Eli Lilly and are expected to grow by 5.56% in the coming year, from $7.56 to $7.98 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eli Lilly and is 33.81, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 31.48.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eli Lilly and is 33.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 38.44.
Price to Earnings Growth Ratio
Eli Lilly and has a PEG Ratio of 1.57. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Eli Lilly and has a P/B Ratio of 73.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$206.92

+6.38 (+3.18 %)

(As of 03/5/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Eli Lilly and (NYSE:LLY) Frequently Asked Questions

Is Eli Lilly and a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last twelve months. There are currently 4 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Eli Lilly and stock.
View analyst ratings for Eli Lilly and or view top-rated stocks.

What stocks does MarketBeat like better than Eli Lilly and?

Wall Street analysts have given Eli Lilly and a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eli Lilly and wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Eli Lilly and's next earnings date?

Eli Lilly and is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Eli Lilly and.

How can I listen to Eli Lilly and's earnings call?

Eli Lilly and will be holding an earnings conference call on Tuesday, April 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) posted its quarterly earnings results on Thursday, January, 28th. The company reported $2.75 earnings per share for the quarter, topping analysts' consensus estimates of $2.35 by $0.40. The company earned $7.44 billion during the quarter, compared to the consensus estimate of $7.27 billion. Eli Lilly and had a trailing twelve-month return on equity of 166.45% and a net margin of 24.01%. The company's revenue was up 21.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.73 earnings per share.
View Eli Lilly and's earnings history.

How has Eli Lilly and's stock price been impacted by COVID-19 (Coronavirus)?

Eli Lilly and's stock was trading at $140.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LLY stock has increased by 47.8% and is now trading at $206.92.
View which stocks have been most impacted by COVID-19.

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and declared a quarterly dividend on Monday, December 14th. Investors of record on Friday, February 12th will be paid a dividend of $0.85 per share on Wednesday, March 10th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 1.64%. The ex-dividend date is Thursday, February 11th. This is a boost from Eli Lilly and's previous quarterly dividend of $0.74.
View Eli Lilly and's dividend history.

Is Eli Lilly and a good dividend stock?

Eli Lilly and pays an annual dividend of $3.40 per share and currently has a dividend yield of 1.68%. Eli Lilly and does not yet have a strock track record of dividend growth. The dividend payout ratio of Eli Lilly and is 56.29%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 42.61% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.
View Eli Lilly and's dividend history.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and updated its FY21 earnings guidance on Friday, January, 29th. The company provided earnings per share (EPS) guidance of $7.75-8.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.19. The company issued revenue guidance of $26.5-28.0 billion, compared to the consensus revenue estimate of $27.60 billion.

What price target have analysts set for LLY?

15 brokers have issued 12-month target prices for Eli Lilly and's stock. Their forecasts range from $144.00 to $235.00. On average, they expect Eli Lilly and's share price to reach $192.60 in the next twelve months. This suggests that the stock has a possible downside of 6.9%.
View analysts' price targets for Eli Lilly and or view top-rated stocks among Wall Street analysts.

Who are Eli Lilly and's key executives?

Eli Lilly and's management team includes the following people:

Mr. David A. Ricks, Chairman, CEO & Pres (Age 53, Pay $4.4M) (LinkedIn Profile)
Mr. Joshua L. Smiley, Sr. VP & CFO (Age 51, Pay $2.13M)
Dr. Daniel M. Skovronsky, Sr. VP, Chief Scientific Officer & Pres of Lilly Research Labs (Age 48, Pay $2.14M) (LinkedIn Profile)
Mr. Jacob S. Van Naarden, Chief Operating Officer of Loxo Oncology (Age 36)
Mr. Donald A. Zakrowski, Chief Accounting Officer & VP of Fin.
Mr. Martin Bott MIBS, VP of Fin. & Special Projects (Age 58)
Ms. Aarti Shreyas Shah Ph.D., Sr. VP & Chief Information and Digital Officer (Age 57)
Kevin Hern, VP of Investor Relations
Ms. Melissa Stapleton Barnes, Sr. VP of Enterprise Risk Management and Chief Ethics & Compliance Officer (Age 53) (LinkedIn Profile)
Ms. Anat Hakim J.D., Sr. VP, Gen. Counsel & Sec. (Age 52)

What is David A. Ricks' approval rating as Eli Lilly and's CEO?

399 employees have rated Eli Lilly and CEO David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among Eli Lilly and's employees.

Who are some of Eli Lilly and's key competitors?

Some companies that are related to Eli Lilly and include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Endo International (ENDP) and Supernus Pharmaceuticals (SUPN).
View all of LLY's competitors.

What other stocks do shareholders of Eli Lilly and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), The Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Who are Eli Lilly and's major shareholders?

Eli Lilly and's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.15%), Primecap Management Co. CA (3.84%), FMR LLC (2.68%), Price T Rowe Associates Inc. MD (1.26%), Northern Trust Corp (1.13%) and Bank of New York Mellon Corp (0.97%). Company insiders that own Eli Lilly and stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, Christi Shaw, David A Ricks, Donald A Zakrowski, Jackson P Tai, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill and Stephen F Fry.
View institutional ownership trends for Eli Lilly and.

Which major investors are selling Eli Lilly and stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Jennison Associates LLC, BlackRock Inc., Nuveen Asset Management LLC, Primecap Management Co. CA, AJO LP, Winslow Capital Management LLC, and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Eli Lilly and company stock in the last year include Aarti S Shah, Alfonso G Zulueta, Lilly Endowment Inc, Melissa S Barnes, and Stephen F Fry.
View insider buying and selling activity for Eli Lilly and or view top insider-selling stocks.

Which major investors are buying Eli Lilly and stock?

LLY stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Price T Rowe Associates Inc. MD, Avidity Partners Management LP, Brandywine Global Investment Management LLC, Lord Abbett & CO. LLC, Clearbridge Investments LLC, Morgan Stanley, and Fisher Asset Management LLC. Company insiders that have bought Eli Lilly and stock in the last two years include Anne E White, David A Ricks, Jackson P Tai, and Joshua L Smiley.
View insider buying and selling activity for Eli Lilly and or or view top insider-buying stocks.

How do I buy shares of Eli Lilly and?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eli Lilly and's stock price today?

One share of LLY stock can currently be purchased for approximately $206.92.

How much money does Eli Lilly and make?

Eli Lilly and has a market capitalization of $198.32 billion and generates $22.32 billion in revenue each year. The company earns $8.32 billion in net income (profit) each year or $6.04 on an earnings per share basis.

How many employees does Eli Lilly and have?

Eli Lilly and employs 35,065 workers across the globe.

Does Eli Lilly and have any subsidiaries?

The following companies are subsidiares of Eli Lilly and: 1096401 B.C. Unlimited Liability Company, ARMO BioSciences Inc, ARMO Bioscience, Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma, Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Dermira, Devices for Vascular Intervention(DVI), Disarm Therapeutics, Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services Inc, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly de Centro America S.A., Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc, Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, Kinsale Financial Services Unlimited Company, Lilly (Shanghai) Management Co. Ltd, Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly China Research and Development Co. Ltd., Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Lylly Centre for Clinical Pharmacology PTE. LTD., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Pharmaserve-Lilly S.A.C.I., Physio-Control, SGX Pharmaceuticals, SGX Pharmaceuticals Inc, Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.

When was Eli Lilly and founded?

Eli Lilly and was founded in 1876.

What is Eli Lilly and's official website?

The official website for Eli Lilly and is www.lilly.com.

Where are Eli Lilly and's headquarters?

Eli Lilly and is headquartered at LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285.

How can I contact Eli Lilly and?

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]

This page was last updated on 3/8/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here